Minoryx Therapeutics Employee Directory
Biotechnology ResearchCatalonia, Spain11-50 Employees
Minoryx Therapeutics is a biotechnology research company developing therapies for orphan central nervous system diseases. Its lead program, leriglitazone (MIN-102), is a brain-penetrant, selective PPAR gamma agonist being developed for X-linked Adrenoleukodystrophy (X-ALD) and other orphan CNS diseases. Founded in 2011, the company is headquartered in Mataró, Catalonia, Spain, with facilities in Belgium and is supported by a syndicate of experienced investors. Minoryx operates at the registration-stage of biotech development and maintains information via its website at https://minoryx.com. The organization has attracted significant funding to advance its clinical programs.